CareDx partners with 10x Genomics on transplant rejection research program

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. SPCX
2. SBUX
3. LEVI
4. HUM
5. NVDA
6. CMG
7. ALHC
8. STZ
9. AAPL
10. SPY

Go back to CareDx partners with 10x Genomics on transplant rejection research program

CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response

January 7, 2026 7:05 AM EST

Collaboration will engage leading transplant clinician-scientists to study antibody-mediated rejection (AMR) and microvascular inflammation (MVI) using cellular-resolution profiling

BRISBANE, Calif.--(BUSINESS WIRE)-- CareDx, Inc. (Nasdaq: CDNA) The Transplant Company a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers today announced a strategic collaboration with 10x Genomics (Nasdaq: TXG), a leader in single cell and spatial biology, to establish ImmuneScape, a multiomics research initiative designed by CareDx to elucidate the biology of transplant organ... More